South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011 to more than $550 million in 2016, according to a new report from health care advisory firm Decision Resources, titled Type 2 Diabetes in South Korea.

Market growth will be fueled by the increasing use of DPP-IV inhibitors, GLP-1 receptor agonists and insulin analogues as well as the introduction of the novel SGLT-2 inhibitor drug class. As in the major Western markets, the biguanide metformin is and will remain the leading option for the treatment of type 2 diabetes in South Korea owing to its low cost and long-term physician familiarity.

Merck & Co’s Januvia and Janumet top multinational brands